Doma Appoints Dr. Jun Song as Chief Strategy Officer


    On January 29, 2024, Beijing Time, Doma announced the appointment of Dr. Jun Song as the company's chief strategy officer. Dr. Song assumes the role of leading Doma's strategic and product line planning and the expansion of international collaborations for the company's pipelines.



    Dr. Song possesses an international perspective and extensive experience, having spent over 15 years in R&D and sales expansion for both innovative and generic drugs, as well as several years of expertise in cooperative management, product line management, international market development, and supply chain management. Dr. Song received her Ph.D. from the Medical College of Ohio (now the University of Toledo) in 2007, with a major in Cellular and Molecular Biology and a minor in bioinformatics. Before joining Doma, Dr. Song served as the head and executive director of R&D business development in China for the Global Business Development Department at Novartis. She has also held key roles at companies such as Meda and Pfizer China. Dr. Song also has several years of experience as a practicing clinician.

    "I am pleased to be part of Doma and to work alongside the young and dynamic team here," said Dr. Song. "Doma is an innovation-driven company that leverages its unique biological advantages to align closely with the pulse of biomedical innovation in China and beyond. The next stage of global biomedical innovation will fully utilize in-depth human biology research to address unmet clinical needs and alleviate clinical pain points. I am confident that Doma will carve out its own path of innovation in the field of biomedical research, benefiting doctors and patients worldwide."

    The Board of Directors of Doma stated that: We are delighted to welcome Dr. Song to Doma! With her extensive experience in innovative drug R&D and business expansion, she is expected to contribute significantly to the company's global business expansion as our Bispecific ADC pipelines DM001, DM002, and DM005 advance towards FDA IND application. We believe that Dr. Song will guide our team in efficiently driving international collaborations for our innovative drug pipelines, ultimately positioning Doma as a world-leading biopharmaceutical company.